Wells Fargo
CSTL icon

Wells Fargo’s Castle Biosciences CSTL Stock Holding History

Wells Fargo’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$316K Sell
12,892
-21,320
-62% -$698K ﹤0.01% 4412
2025
Q4 		$1.33M Buy
34,212
+10,233
+43% +$330K ﹤0.01% 3746
2025
Q3 		$546K Buy
23,979
+3,679
+18% +$74.7K ﹤0.01% 4247
2025
Q2 		$415K Buy
20,300
+3,953
+24% +$73.2K ﹤0.01% 4277
2025
Q1 		$327K Buy
16,347
+972
+6% +$24.1K ﹤0.01% 4372
2024
Q4 		$410K Buy
15,375
+3,460
+29% +$105K ﹤0.01% 4326
2024
Q3 		$340K Buy
11,915
+408
+4% +$10.4K ﹤0.01% 4242
2024
Q2 		$251K Buy
11,507
+2,081
+22% +$46.4K ﹤0.01% 4360
2024
Q1 		$209K Buy
9,426
+1,479
+19% +$32.2K ﹤0.01% 4444
2023
Q4 		$171K Buy
7,947
+1,546
+24% +$27.2K ﹤0.01% 4562
2023
Q3 		$108K Sell
6,401
-5,011
-44% -$87.6K ﹤0.01% 4733
2023
Q2 		$157K Buy
11,412
+5,578
+96% +$113K ﹤0.01% 4733
2023
Q1 		$133K Sell
5,834
-18,247
-76% -$446K ﹤0.01% 4677
2022
Q4 		$567K Buy
24,081
+19,979
+487% +$463K ﹤0.01% 3567
2022
Q3 		$107K Buy
4,102
+838
+26% +$23.5K ﹤0.01% 4566
2022
Q2 		$71K Sell
3,264
-101,099
-97% -$2.35M ﹤0.01% 4845
2022
Q1 		$4.68M Sell
104,363
-3,359
-3% -$139K ﹤0.01% 2506
2021
Q4 		$4.62M Sell
107,722
-462,813
-81% -$24.2M ﹤0.01% 2653
2021
Q3 		$37.9M Buy
570,535
+62,997
+12% +$4.43M 0.01% 1228
2021
Q2 		$37.2M Sell
507,538
-6,353
-1% -$420K 0.01% 1254
2021
Q1 		$35.2M Sell
513,891
-77,215
-13% -$5.8M 0.01% 1252
2020
Q4 		$39.7M Sell
591,106
-12,425
-2% -$674K 0.01% 1116
2020
Q3 		$31.1M Buy
603,531
+46,058
+8% +$2.05M 0.01% 1134
2020
Q2 		$21M Buy
557,473
+296,960
+114% +$10.1M 0.01% 1345
2020
Q1 		$7.77M Buy
260,513
+254,404
+4,164% +$7.68M ﹤0.01% 1870
2019
Q4 		$210K Buy
6,109
+2,510
+70% +$61.4K ﹤0.01% 4923
2019
Q3 		$65K Buy
+3,599
New +$79.8K ﹤0.01% 5480

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo's CSTL Position: Q1 2026 in Review

Wells Fargo reduced its Castle Biosciences (CSTL) stake by 62% in Q1 2026, selling an estimated $698K and leaving 12,892 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #4412.

Wells Fargo first reported a position in CSTL in Q3 2019 and has held it in 27 quarters since. The position peaked at $39.7M in Q4 2020. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Wells Fargo held 12,892 shares of Castle Biosciences worth $316K as of Q1 2026.
  • Wells Fargo sold 21,320 Castle Biosciences shares in Q1 2026, an estimated $698K.
  • Castle Biosciences made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4412 holding.
  • Wells Fargo first reported a position in Castle Biosciences in Q3 2019 and has held it in 27 quarters since.
  • Wells Fargo's Castle Biosciences position peaked at $39.7M in Q4 2020.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.